candesartan cilexetil has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Enya, K; Kaku, K; Sugiura, K; Totsuka, N | 1 |
1 trial(s) available for candesartan cilexetil and pioglitazone
| Article | Year |
|---|---|
Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Single-Blind Method; Tetrazoles; Thiazolidinediones | 2011 |
1 other study(ies) available for candesartan cilexetil and pioglitazone
| Article | Year |
|---|---|
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARĪ³ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |